Beovu 6 mg/0.05 ml (IV Infusion)

Indications

• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)

Pharmacology

• VEGF inhibitor
• Binds to VEGF-A isoforms (e.g., VEGF 110, VEGF 121, and VEGF 165)
• Prevents interaction with VEGFR-1 and VEGFR-2
• Suppresses endothelial cell proliferation
• Suppresses neovascularization
• Suppresses vascular permeability

Dosage & Administration

• Recommended dose for Neovascular AMD: 6 mg monthly for first three doses, then 6 mg every 8-12 weeks
• Recommended dose for DME: 6 mg every six weeks for first five doses, then 6 mg every 8-12 weeks
• Pediatric use safety and efficacy not established

Contraindications

• Ocular or Periocular Infections
• Active Intraocular Inflammation
• Hypersensitivity to brolucizumab or any excipients

Side Effects

• Blurred vision
• Cataract
• Conjunctival hemorrhage
• Eye pain
• Vitreous floaters

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Fetal loss and structural abnormality observed in animal reproduction study
• Not recommended during breastfeeding

Precautions & Warnings

• Endophthalmitis and retinal detachment may occur following intravitreal injections
• Retinal vasculitis and/or retinal vascular occlusion reported
• Increases in intraocular pressure (IOP) seen within 30 minutes of injection
• Potential risk of arterial thromboembolic events following intravitreal use

Storage Conditions

• Refrigerate between 2°C to 8°C
• Do not freeze
• Store in outer carton to protect from light
• Unopened vial or blister pack may be kept at room temperature for up to 24 hours

Related Brands